Moderna, Inc.

The forensic screens are not on file for this company, so this synthesis reports no Beneish M-Score, Piotroski F-Score, Altman Z-Score or Fog Index value, and none should be inferred from the figures here. That gap matters because the financial facts alone show a large and rapid shift. Revenue reached $19.26 billion in 2022 and $18.47 billion in 2021, then fell to $6.85 billion in 2023, $3.24 billion in 2024 and $1.94 billion in 2025. Those are declines of roughly 53 percent in 2024 and about 40 percent in 2025. Over the same stretch the company moved from a net profit of $8.36 billion in 2022 to net losses in every year from 2023 through 2025. The 2025 net loss of $2.82 billion is about 21 percent smaller than the 2024 loss, a narrowing that is real but small relative to the revenue decline. Earlier years show a different pattern: net losses of $384.73 million in 2018, $514.02 million in 2019 and $747.06 million in 2020 came before the large revenue increase. A careful reader would want the company's own explanation of why revenue fell, what the cost base looks like, and which programs or contracts drove the earlier surge, none of which appears in the data provided. Without MD&A, risk-factor or news text, the narrative cannot be checked against management's account. The honest reading of this dataset is that the numbers describe a sharp reversal whose causes are not documented here.

Catalyst.The data provided contains no MD&A text, so management's own explanation of current drivers cannot be reported here. The numbers alone show a business in contraction: revenues were $1.94 billion in 2025, down from $3.24 billion in 2024, a decline of about 40 percent, and $6.85 billion in 2023. Operating loss narrowed to $3.07 billion in 2025 from $3.94 billion in 2024, and net loss narrowed to $2.82 billion from $3.56 billion. Readers may want to look at the MD&A section of the company's annual report directly to see what management attributes these changes to.

Hidden risk.A casual reader could miss how quickly the earnings picture reversed. Net income was $12.2 billion in 2021 and $8.36 billion in 2022, but the company recorded net losses of $4.71 billion in 2023, $3.56 billion in 2024, and $2.82 billion in 2025. Operating losses persisted across those three years, and the 2025 operating loss of $3.07 billion exceeded that year's $1.94 billion of revenue. Because no risk-factor text is on file here, this analysis cannot say which of these pressures management has flagged as material. Readers may want to check the risk factors section directly.